Gilead Sciences, Inc. (GILD) Earns “Market Perform” Rating from Leerink Swann
Leerink Swann reissued their market perform rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a report published on Wednesday morning. They currently have a $87.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $82.00.
A number of other brokerages also recently weighed in on GILD. ValuEngine upgraded Gilead Sciences from a buy rating to a strong-buy rating in a report on Thursday, September 7th. TheStreet upgraded Gilead Sciences from a c+ rating to a b- rating in a report on Thursday, September 7th. Zacks Investment Research downgraded Gilead Sciences from a buy rating to a hold rating in a report on Monday, September 11th. Vetr downgraded Gilead Sciences from a buy rating to a hold rating and set a $86.44 price target on the stock. in a report on Monday, September 4th. Finally, Wells Fargo & Company lifted their price target on Gilead Sciences from $73.00 to $81.00 and gave the company a market perform rating in a report on Wednesday, September 6th. Eleven investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. Gilead Sciences presently has a consensus rating of Buy and a consensus price target of $84.29.
Gilead Sciences (GILD) traded up 0.79% during midday trading on Wednesday, reaching $83.27. 5,654,657 shares of the company’s stock traded hands. The stock has a market cap of $108.74 billion, a P/E ratio of 9.04 and a beta of 1.19. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $86.27. The company’s 50-day moving average price is $77.54 and its 200-day moving average price is $70.38.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter in the previous year, the company posted $3.08 earnings per share. Gilead Sciences’s revenue for the quarter was down 8.2% compared to the same quarter last year. On average, equities analysts predict that Gilead Sciences will post $8.78 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Earns “Market Perform” Rating from Leerink Swann” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/23/gilead-sciences-inc-gild-earns-market-perform-rating-from-leerink-swann.html.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is currently 22.58%.
In other news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the transaction, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at $227,197,799. The disclosure for this sale can be found here. Insiders sold a total of 466,819 shares of company stock worth $36,740,240 over the last three months. 1.30% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Gilead Sciences by 583.3% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. boosted its holdings in shares of Gilead Sciences by 19.4% in the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 267 shares in the last quarter. Penserra Capital Management LLC boosted its holdings in shares of Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares in the last quarter. Webster Bank N. A. boosted its holdings in shares of Gilead Sciences by 51.7% in the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 624 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $147,000. 73.97% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.